Vidac Pharma announced that it has received $9 million in its series A round of funding led by new investor Israel Biotech Fund I, L.P., a fund managed by Israel Biotech Fund on June 29, 2016. The round included participation from existing investors including Mivtach Shamir Holdings Ltd. (TASE:MISH). As part of the round, Robert Spiegel and Ed Saltzman of Israel Biotech Fund will join the company’s board of directors.